Astria Therapeutics Inc at Jefferies London Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Eun Yang - Jefferies & Company - Analyst : Okay. So the year-end data that we are expecting, even the highest dose of cohort 2, do you have them been followed at least three months? Is that correct?

Question: Eun Yang - Jefferies & Company - Analyst : I see. And then in terms of looking at the PD biomarker, the cleaved high-molecular kininogen, you speaking about 50% reduction in in-vitro assay similar to Takhzyro. Why not more than 50%? Why is it stopping at 50%?

Question: Eun Yang - Jefferies & Company - Analyst : I see. So Takhzyro, when you look at their data, the number of attacks monthly is reduced by close to 80%, but all attack-free rate is above 40%. Do you think it's because they can now bring it down to cleave the high-molecular kininogen down to like a [0%]?

Question: Eun Yang - Jefferies & Company - Analyst : I see. So we got to see the data but with the three different dosing regimen, do you expect to see those response? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 16, 2022 / 7:25AM, ATXS.OQ - Astria Therapeutics Inc at Jefferies London Healthcare Conference

Question: Eun Yang - Jefferies & Company - Analyst : Okay. In this in-vitro study, obviously, it's more artificial. But can you resume major plasma kallikrein activity after the dose?

Question: Eun Yang - Jefferies & Company - Analyst : No, but this is a kind of biomarker, but kallikrein levels (multiple speakers).

Question: Eun Yang - Jefferies & Company - Analyst : So the data we are going to see is the functional activity but not the enzyme levels?

Question: Eun Yang - Jefferies & Company - Analyst : Are you planning to measure that in the subsequent trials?

Question: Eun Yang - Jefferies & Company - Analyst : Okay. And then Jill showed the non-human primate data showing the plasma half-life increased by 3.5-fold, compared to Takhzyro. And then you mentioned that hey, this product you could take potentially every three months or less frequently. So I get the three-months apart, but less frequently. Where do you get that confidence?

Question: Eun Yang - Jefferies & Company - Analyst : Okay. And then in terms of the market, there are other products in development in HAE, getting a little bit crowded. So particularly the one with the gene editing, it's very early. How do you think a decent market actually plays out? Because by the time you get to the market, gene editing probably might be on the market as well; as well as ASO, other monoclonal type of product.

Question: Eun Yang - Jefferies & Company - Analyst : Yes. So between like a number of monthly attack reduction and attack-free. I mean, I assume that attack-frees are more beneficial clinical endpoints. And with the Takhzyro, it's about 40% reduction. This may be kind of a stupid question, but can you actually combine C1-inhibitor plus plasma kallikrein inhibitor together to bring down attack rate further from 40% to 50% range?

Question: Eun Yang - Jefferies & Company - Analyst : Okay. Thank you very much.